The Study of Pharmacological Treatment Pattern for Cannabis-induced Psychosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

317 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-11-08

Study Completion Date

2020-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A cross-sectional and retrospective chart review study was conducted at the Princess Mother National Institute on Drug Abuse Treatment (PMNIDAT), Thailand. All patients who admitted at PMNIDAT from October 2013 to September 2019 were included. Patients aged 18-65 years who met the International Classification of Disease-10 (ICD-10) criteria of CIP and Had a positive urine test of cannabis were included. Cannabis use is a component cause of psychosis.More than half of symptoms of cannabis-induced psychosis (CIP) were hallucination, delusion, irritable and anxiety. Antipsychotic drug was still a key psychotropic drugs for treatment of CIP. However, antidepressants and benzodiazepines were commonly used for treatment of other symptoms beyond psychotics

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

MEDical CANnabis for Improving Symptoms During Severe DEMentia Disorders in Long-term Care Facility in Geneva

NCT05432206

Dementia with Behavioral Disturbance

COMPLETED PHASE2/PHASE3

Cannabidiol as a Different Type of an Antipsychotic: Drug Delivery and Interaction Study

NCT02051387

Schizophrenia

COMPLETED PHASE1

Investigating the Neural Correlates of Cognitive Function in Psychosis Patients and Non-Psychiatric Controls With Cannabis Use

NCT05445180

Psychotic Disorders Cannabis Use Disorder Cannabis Dependence +5 more

RECRUITING NA

Cannabidiol Treatment in Patients With Early Psychosis

NCT02504151

Schizophrenia Schizoaffective Disorder

COMPLETED PHASE2

A Clinical Trial on the Antipsychotic Properties of Cannabidiol

NCT00309413

Schizophrenia Psychotic Disorders

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cannabis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

cannabis-induced psychosis

cannabis

Intervention Type OTHER

This study is observational study, we recorded history of substance used, symptoms and medication in a medical chart.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

cannabis

This study is observational study, we recorded history of substance used, symptoms and medication in a medical chart.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients ≥ 12 years of age
* Patients who had been diagnosed as Cannabis-induced psychosis by International statistical Classification of Disease and Related Health problem (ICD-10) on 2016 code F12.5
* Patients had history of use of cannabis in medical chart
* Patients had the positive urine screening test of cannabis at the first day of admission

Exclusion Criteria

* Patients had psychosis from organic psychosis, defined by diagnosis by ICD-10 code F09.6
* Unavailable data for evaluate of outcome especially data of drug use, content of drug use or urine screening test
* Patients who cancel of medical treatment before 7 day after admission.

Minimum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No